CureMatch
Latest round
- Series A
Last raised
- Aug 2017
Total raised
- Undisclosed
Investors
- 2
About CureMatch
CureMatch, Inc.CureMatch, Inc. specializes in personalized cancer treatment by offering a sophisticated Decision Support System that analyzes molecular tumor profiles. Founded in 2015, the company operates from San Diego, US. The founders include Blaise Barrelet, Navid Alipour, and Razelle Kurzrock, with Navid Alipour currently serving as CEO.CureMatch, Inc. provides a sophisticated Decision Support System that utilizes advanced algorithms to offer oncologists predictive treatment analyses tailored to individual cancer patients based on their molecular tumor profiles. The core service revolves around their therapy matching and scoring system, which ranks and scores combination drug therapies specifically targeting a patient’s genomic data, regardless of the cancer type diagnosed. This service is designed to help oncologists select optimal treatment options, thereby increasing progression-free survival rates for patients. The primary clientele consists of oncologists, cancer centers, next-generation sequencing (NGS) laboratories, and concierge medicine providers, who rely on CureMatch's actionable insights to improve patient outcomes.CureMatch operates on a B2B model, primarily generating revenue through partnerships with healthcare providers and institutions that utilize its therapy matching services. The transactions typically involve healthcare facilities subscribing to CureMatch's services, allowing oncologists to access tailored treatment analyses for their patients. This partnership structure enables oncologists to leverage the proprietary algorithms to enhance their decision-making capabilities in cancer treatment. CureMatch's services include a therapy matching system that was recently granted a Category III CPT code, facilitating reimbursement processes for oncologists integrating these services into their practices. The company is focusing on developing new products that enhance its therapy matching capabilities, with plans to potentially release updates within the next year. Furthermore, CureMatch aims to extend its services into additional international markets, particularly in regions where personalized cancer treatments are gaining prominence, with targeted expansion efforts expected over the next two years.
Who invested in CureMatch
2 investors across 2 rounds
See all investors in CureMatch
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CureMatch
Who invested in CureMatch?
CureMatch has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CureMatch raised?
CureMatch has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CureMatch last raise money?
CureMatch's most recent round on record is a Series A, in Aug 2017.
What does CureMatch do?
CureMatch is a healthcare it company.
Where is CureMatch headquartered?
CureMatch is headquartered in San Diego, US.
Which VCs invest in companies like CureMatch?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare it companies at CureMatch's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series A
Raising like CureMatch? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.